The software pre-certification program, which the FDA presented its initial version for in April, aims to streamline approval for digital health technologies by reviewing developers, rather than individual products. These pre-certified developers would be able launch products without review, so long as the developers collect post-market data to confirm product safety to the FDA.
The underlying premise of the program is that digital health products should be evaluated differently than traditional medical devices, since software is updated more frequently. The FDA established the program based on the idea a trustworthy software developer will likely continue to put out high-quality products, according to the Politico Morning eHealth newsletter.
The FDA plans to launch a large-scale pilot in 2019, building on lessons learned during its initial pilot with nine digital health companies, which included tech giants like Apple and Fitbit.
A key update within the new 45-page working model for the software pre-certification program involves the FDA’s intention to expand the program to software used within traditional medical devices, such as programs that operate within an X-ray machine, according to Politico‘s newsletter.
To access the FDA’s updated plan, click here.
More articles on supply chain:
FDA approves 1st glucose monitoring system with implantable sensor, monitoring app
Several New York hospitals are running dangerously low on blood
IBM, Pfizer join blockchain consortium for accountability in digital advertising
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
